A practical guide for the management of gliomas;Un guide pratique au traitement des gliomes

Bulletin du Cancer

Volumn 94, Issue 9, 2007, Pages 817-822

  Stupp, Roger ^a   Pica, Alessia ^a   Mirimanoff, René O ^a   Michielin, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Glioma; Guidelines

Indexed keywords

ALKYLATING AGENT; METHYL GUANINE METHYLTRANSFERASE; MOLECULAR MARKER; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ASTROCYTOMA; CANCER SURVIVAL; GENE IDENTIFICATION; GLIOBLASTOMA; GLIOMA; HUMAN; METHYLATION; OLIGODENDROGLIOMA; PRACTICE GUIDELINE; PREDICTION; PROMOTER REGION; REVIEW; TREATMENT RESPONSE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DISEASE MANAGEMENT; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GLIOMA; HUMANS; TREATMENT OUTCOME;

EID: 35148842445     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0448     Document Type: Review

References (51)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon : IARC Press, 2000.
2. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002 ; 61 : 215-25 ; (discussion 226-9).
3. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma : standard of care and future directions. J Clin Oncol 2007 : 25.
4. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist 2006 ; 11 : 165-80.
5. Stupp R, Janzer RC, Hegi ME, et al. Prognostic factors for low-grade gliomas. Semin Oncol 2003 ; 30 : 23-8.
6. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas : a cooperative clinical trial. J Neurosurg 1978 ; 49 : 333-43.
7. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980 ; 303 : 1323-9.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 : 987-96.
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 352 : 997-1003.
10. Stupp R, Dietrich P, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002 ; 20 : 1375-82.
11. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 : 1871-4.
12. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide : a toxicity with therapeutic implications. J Clin Oncol 2004 ; 22 : 610-6.
13. Ganiere V, Christen G, Bally F, et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 2006 ; 3 : 339-43.
14. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007 ; 356 : 1527-35.
15. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme : a prospective randomized clinical trial. J Clin Oncol 2004 ; 22 : 1583-8.
16. Stupp R, Rüegg C. New drugs and combinations for malignant glioma. Forum 2005 ; 13 : 61-75.
17. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999 ; 17 : 2572.
18. Yung A, Levin V, Albright R, et al. Randomized trial of Temodal vs. procarbazine in glioblastoma multiforme at first relapse. Proc Am Soc Clin Oncol 1999 : 18.
19. Brada M, Hoang-Xuang K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001 ; 12 : 59-266.
20. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003 ; 88 : 1004-11.
21. Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004 ; 62 : 2113-5.
22. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005 ; 23 : 4235-6.
23. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999 ; 17 : 1516-25.
24. Reardon DA, Friedman HS, Powell JB, et al. Irinotecan : promising activity in the treatment of malignant glioma. Oncology 2003 ; 17 : 9-14 ; (Huntingt).
25. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 2003 ; 14 : 603-14.
26. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005 ; 23 : 9359-68.
27. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004 ; 22 : 133-42.
28. Van den Bent M, Brandes A, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme : EORTC 26034. Asco annual meeting proceedings. J Clin Oncol 2007 ; 25 : 765 ; abst. 2004.
29. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989 ; 71 : 1-9.
30. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989 ; 16 : 1389-96.
31. Hildebrand J, De Witte O, Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibfomodulcitol, BCNU and procarbazine : a phase-II study. J Neurooncol 1998 ; 37 : 155-60.
32. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999 ; 17 : 2762-71.
33. Van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998 ; 51 : 1140-5.
34. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 ; 90 : 1473-9.
35. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994 ; 12 : 2013-21.
36. Friedman A, Cokgor I, Edwards S, et al. Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temozolomide. Proc Am Soc Clin Oncol 2000 ; 19 : 169a (abstract #654).
37. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma : implications for patient management at diagnosis. Clin Cancer Res 2001 ; 7 : 839-45.
38. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 ; 18 : 636-45.
39. Reifenberger G, Louis DN. Oligodendroglioma : toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003 ; 62 : 111-26.
40. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005 ; 113 : 379-85.
41. Stupp R, Hegi ME. Neuro-oncology : oligodendroglioma and molecular markers. Lancet Neurol 2007 ; 6 : 10-2.
42. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006 ; 66 : 9852-61.
43. Cairncross JG, Macdonald DR. Oligodendroglioma : a new chemosensitive tumor. J Clin Oncol 1990 ; 8 : 2090-1.
44. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 ; 24 : 2707-14.
45. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 2006 ; 24 : 2715-22.
46. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma : European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996 ; 36 : 549-56.
47. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma : initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Coopetative Oncology Group study. J Clin Oncol 2002 ; 20 : 2267-76.
48. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult : European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4 : an interim analysis. Int J Radiat Oncol Biol Phys 2002 ; 52 : 316-24.
49. Van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised trial. Lancet 2005 ; 366 : 985-90.
50. Shaw E, Berkey B, Coons S, et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802 : Prospective studies in adult low-grade glioma (LGG). J Clin Oncol 2006 (suppl) : 24.
51. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002 ; 20 : 2076-84.